Human/JJ
immunodeficiency/NN
virus/NN
type-2/JJ
gene/NN
expression/NN
:/:
two/CD
enhancers/NNS
and/CC
their/PRP$
activation/NN
by/IN
T-cell/NN
activators/NNS
./.

The/DT
human/JJ
immunodeficiency/NN
viruses/NNS
(/(
HIVs/NNS
)/)
may/MD
include/VB
a/DT
spectrum/NN
of/IN
retroviruses/NNS
with/IN
varying/VBG
potential/NN
to/TO
infect/VB
their/PRP$
host/NN
,/,
undergo/VB
long/JJ
periods/NNS
of/IN
latent/JJ
infection/NN
,/,
and/CC
induce/VB
pathology/NN
./.
=====
Since/IN
expression/NN
of/IN
the/DT
viruses/NNS
is/VBZ
in/IN
large/JJ
part/NN
regulated/VBN
by/IN
the/DT
sequence/NN
elements/NNS
in/IN
their/PRP$
long/JJ
terminal/JJ
repeats/NNS
(/(
LTRs/NNS
)/)
,/,
this/DT
study/NN
was/VBD
directed/VBN
to/TO
an/DT
analysis/NN
of/IN
the/DT
regulatory/JJ
elements/NNS
in/IN
the/DT
HIV-2/NN
LTR/NN
./.
=====
The/DT
HIV-2/NN
LTR/NN
was/VBD
found/VBN
to/TO
contain/VB
two/CD
enhancers/NNS
./.
=====
One/CD
of/IN
these/DT
enhancers/NNS
is/VBZ
,/,
in/IN
part/NN
,/,
identical/JJ
to/TO
the/DT
HIV-1/NN
enhancer/NN
./.
=====
This/DT
enhancer/NN
in/IN
HIV-1/NN
is/VBZ
the/DT
T-cell/NN
activation/NN
response/NN
element/NN
;/:
in/IN
HIV-2/NN
,/,
however/RB
,/,
it/PRP
is/VBZ
the/DT
second/JJ
enhancer/NN
that/WDT
is/VBZ
mainly/RB
responsible/JJ
for/IN
activation/NN
in/IN
response/NN
to/TO
T-cell/NN
activators/NNS
./.
=====
The/DT
second/JJ
enhancer/NN
interacts/VBZ
with/IN
two/CD
nuclear/JJ
binding/NN
proteins/NNS
(/(
85/CD
kD/NN
and/CC
27/CD
kD/NN
mobility/NN
)/)
that/WDT
appear/VBP
to/TO
be/VB
required/VBN
for/IN
optimal/JJ
enhancer/NN
function/NN
and/CC
activation/NN
./.
=====
Observations/NNS
such/JJ
as/IN
these/DT
encourage/VBP
the/DT
speculation/NN
that/IN
there/EX
may/MD
be/VB
subtle/JJ
differences/NNS
in/IN
the/DT
regulation/NN
of/IN
HIV-1/NN
and/CC
HIV-2/NN
expression/NN
that/WDT
may/MD
be/VB
relevant/JJ
to/TO
the/DT
possible/JJ
longer/JJR
latency/NN
and/CC
reduced/VBN
pathogenicity/NN
of/IN
HIV-2/NN
./.